Windlas Biotech Ltd
NSE:WINDLAS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (18.6), the stock would be worth ₹760.59 (13% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 21.4 | ₹878.05 |
0%
|
| 3-Year Average | 18.6 | ₹760.59 |
-13%
|
| 5-Year Average | 14.5 | ₹593.61 |
-32%
|
| Industry Average | 29.1 | ₹1 191.31 |
+36%
|
| Country Average | 23.3 | ₹952.98 |
+9%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Windlas Biotech Ltd
NSE:WINDLAS
|
18.4B INR | 21.4 | 27.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 360.7 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.4B USD | 26.8 | 28.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
130.1B USD | 26.8 | 36 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.1B CHF | 26.7 | -124.9 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
296.1B CNY | 16 | 15.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD | 22.9 | 26.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.8B USD | 41.4 | 51 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD | 18.2 | 22 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 25.2 | 30.7 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
Windlas Biotech Ltd
Glance View
Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The Company’s market its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
